Pannexin-1 promotes CD8+ T cell antitumor immunity against colorectal cancer in a gender-dependent way 2256739
Colorectal cancer (CRC) is the second leading cause of cancer death in the U.S., with stage IV patients showing poor five-year survival. Immune checkpoint blockade shows limited efficacy in CRC, highlighting the need to better understand how CD8+ T cells are regulated by the tumor microenvironment (TME). In the T...